Overview

Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.

Status:
Completed

Trial end date:
2005-07-01

Target enrollment:
0

Participant gender:
All

Summary

To evaluate long-term efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Pregabalin

Criteria

Inclusion Criteria:

- Must have met the inclusion criteria for preceding double-blind study

- Must have received pregabalin or amitriptyline or placebo under double-blind
conditions under double-blind conditions at least during first 3 weeks if double-blind
treatment phase of preceding study.

Exclusion Criteria:

- Patients cannot be included if they experienced a serious adverse event while
participating in preceding double-blind study, which was determined to be related to
the study medication.